Highlights Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
8.33 ^USD	+6.52%		+4.91%	-15.52%

Apr. 18	Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	MT
Apr. 16	Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Recursion Pharmaceuticals to Open London Office	Mar. 11	MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat	Feb. 28	MT
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q4 Revenue $10.9M	Feb. 27	MT
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Nvidia Discloses Investment Stakes in AI Firms; Shares Jump	Feb. 15	MT
Arm, SoundHound AI shares jump as Nvidia builds stake	Feb. 15	RE
Recursion Unveils Lowe Drug Discovery Software At the J.P. Morgan Healthcare Conference	Jan. 08	CI
Recursion Pharmaceuticals Shares Climb on Accord With Bayer for Possible Treatment of Fibrotic Diseases	Jan. 04	MT
Recursion Pharmaceuticals Shares Rise on Accord With Bayer for Possible Treatment of Fibrotic Diseases	Jan. 04	MT
Recursion Pharmaceuticals Partners With Enamine to Design Compound Libraries for Drug Discovery	Dec. 20	MT
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry	Dec. 20	CI
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Posts Q3 Revenue $10.5M	Nov. 09	MT
Recursion Pharmaceuticals, Inc. Announces Completion of Phase 1 Study for Rec-3964 for Clostridioides Difficile Infection	23-09-05	CI
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q2 Revenue $11M	23-08-08	MT
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Recursion Pharmaceuticals, Inc. Launches Valence Labs At International Conference on Machine Learning	23-07-26	CI
Recursion Pharmaceuticals Shares Soar After $50 Million Investment From NVIDIA	23-07-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Highlights

Filters